Full-Time

Senior Associate Scientist

Protein Science

Confirmed live in the last 24 hours

Generation Bio

Generation Bio

51-200 employees

Develops durable genetic treatments for diseases

Biotechnology
Healthcare

Junior, Mid, Senior

Cambridge, MA, USA

Headquartered in Cambridge, Massachusetts.

Category
Lab & Research
Life Sciences
Requirements
  • M.S. or B.S. with a minimum of 2 years of relevant experience, industry experience preferred
  • Hands-on experience and knowledge of protein purification using HIC, IEX, SEC and affinity chromatography. Experience with GE AKTA FPLC is preferred.
  • Excellent lab technique and the ability to work independently to analyze, interpret, and present data
  • Proficiency in biochemical and biophysical characterization methods (e.g. ELISA, DSC, DSF, SDS-PAGE, BLI, SPR, SEC-MALS, flow cytometry) is desired
  • Ability to multi-task to support multiple projects across platform discovery organization
  • Ability to work in a highly collaborative, team-based environment
  • Excellent written and verbal communication skills
Responsibilities
  • Perform a range of biochemical techniques such as ELISA, MSD, Western blotting, SDS-PAGE, and flow cytometry to characterize protein expression and function.
  • Perform a range of biophysical techniques such as surface plasmon resonance (SPR), biolayer Interferometry (BLI), size-exclusion chromatography – multiangle light scattering (SEC-MALS), and differential scanning calorimetry (DSC) or fluorimetry (DSF) to characterize protein-ligand interactions and protein stability.
  • Assist to analyze and interpret data from biophysical assays to understand binding kinetics, thermodynamics, and binding affinities.
  • Assist to troubleshoot and optimize assays as needed to improve sensitivity, specificity, and reproducibility.
  • Maintain accurate and up-to-date laboratory records.
  • Routinely present updates at group meetings

Generation Bio focuses on developing long-lasting and repeatable genetic treatments for both rare and common diseases. Their main product is based on a unique non-viral genetic medicine platform that includes iqDNA, which is designed to avoid triggering immune responses, and ctLNP, a system that delivers genetic material directly to specific cells. They use a manufacturing process called rapid enzymatic synthesis (RES) that allows them to produce iqDNA efficiently and at scale, potentially creating hundreds of millions of doses. This process not only enables the delivery of large amounts of genetic information to targeted tissues but also allows for adjustments in treatment through redosing. Generation Bio aims to make genetic medicine more accessible to a wider range of patients by addressing significant medical needs in the field.

Company Stage

IPO

Total Funding

$252.9M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-22%

2 year growth

-15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic reorganization extends cash runway into 2H 2027, supporting long-term R&D.
  • Collaboration with Moderna highlights market interest in non-viral delivery systems.
  • Focus on extrahepatic cell types could expand therapeutic areas and market reach.

What critics are saying

  • 40% workforce reduction may impact development timelines for ctLNP and iqDNA platforms.
  • Potential competition from companies like Moderna in non-viral genetic therapies.

What makes Generation Bio unique

  • Generation Bio uses a non-viral platform for durable, redosable genetic therapies.
  • Their immune-quiet DNA (iqDNA) evades host immune detection, reducing side effects.
  • The company employs a scalable, capsid-free manufacturing process for efficient production.

Help us improve and share your feedback! Did you find this helpful?